MEMBER

• 

  Representative Director, CEO and founder
  Akinori Mochizuki, Ph. D.

  Dr. Mochizuki has about 30 years of work experience in pharmaceutical industry; covering from basic science such as molecular and cellular biology, in vivo pharmacology, drug repositioning, CMC and aseptic product development, to various business skills including business development, intellectual property management on top of corporate management. After graduated from Tokyo University of Pharmacy and Life Sciences, he started his career at pharmaceutical company along with obtaining Ph. D. degree in Medicine at Toho University School Of Medicine, and he then moved to well-known Japanese biotech venture company Sosei Group, where he acquired most of his business skills as an executive officer and CSO.
  He started Vetanic together with Dr. Edamura and Dr. Shiozawa in 2021 with the goal to make iPS cell-technology as a practical therapy in veterinary field.

• 

  External Director, CSO and co-founder
  Professor, Laboratory of Veterinary Surgery, Department of Veterinary Medicine, College of Bioresource and Sciences, Nihon University; Director of Animal Medical Center (ANMEC) of Nihon University Kazuya Edamura, DVM, Ph. D.

  Dr. Edamura graduated from the Department of Veterinary Medicine, College of Agriculture and Veterinary Medicine, Nihon University, and obtained a license of Japanese Veterinarian. He has completed the Graduate School of Agricultural and Life Sciences, The University of Tokyo, and obtained Ph. D. Degree. In same years, he joined the Laboratory of Veterinary Surgery, Department of Veterinary Medicine, College of Bioresource Sciences, Nihon University as an assistant professor, and is currently a professor.
  He has become a director of Animal Medical Center （ANMEC） of Nihon University where he is also responsible as a Diplomate of Japanese College of Veterinary Surgeons （Dipl. JCVS） in orthopedic surgery. His main research areas are veterinary surgery, musculoskeletal diseases, regenerative medicine, and physical therapy. Today, he is the Vice President of the Japanese Society of Veterinary Regenerative Medicine and the Vice President of the Consortium for the Promotion of Animal Regenerative Medicine （CARM） as well.

• 

  External Director, CTO and co-founder
  Professor, Institute for Disease Modeling, Kurume University School of Medicine; Project Associate Professor, Keio University School of Medicine Seiji Shiozawa, DVM, Ph. D.

  Dr. Shiozawa is a co-founder and external director of Vetanic. His expertise lie in stem cell biology, regenerative medicine, and genetic engineering. Together with Dr. Kazuya Edamura, he has developed the method for establishing animal iPS cells, which is Vetanic's core technology.
  He graduated from Nihon University Department of Veterinary Medicine in 2002 and obtained his veterinary license. He then received his Ph.D. in Medicine from the University of Tokyo in 2006. Afterwards, he worked at Hideyuki Okano's lab at Keio University, where he conducted research on neurodegenerative diseases utilizing iPS cell models.
  He is currently a professor at Kurume University School of Medicine and holds a concurrent position as a project associate professor at Keio University School of Medicine.

• 

  External Director
  Keio Innovation Initiative, Inc. Principal Yuto Torii, DVM, MBA

  Dr. Torii graduated from the School of Veterinary Medicine at Hokkaido University.
  After working as a veterinarian, he moved to sales and marketing at Eli Lilly and Company. Then, after completing an MBA, he started a new career at Elanco. In his role in the Corporate Planning department, he was in charge of the Eli Lilly and Company spin-off project, the Bayer integration project, and the development of corporate strategy.
  In 2020, he joined KII as a venture capitalist specializing in the medical healthcare field. He has been serving as an outside director of Vetanic from 2021.

• 

  External Director
  QB Capital, LLC Investment Manager Noriyuki Kawata, Ph. D.

  Dt. Kawata graduated from Tokyo Institute of Technology Graduate School, then he has obtained a doctorate in social engineering from Nagoya Institute of Technology Graduate School. After engaging in R&D of new businesses at a glass manufacturer, he belonged to a consulting firm. At the firm, he dedicated to business operation and patent management including licensing as a director at a subsidiary bio-startup. In 2016, he joined QB Capital and has engaged in not only investment in deep-tech startups but also management of commercialization projects based on university technologies.